MicroRNAs regulating apolipoprotein B-containing lipoprotein production

Zhou, Liye; Irani, Sara; Sirwi, Alaa; Hussain, M. Mahmood

doi:10.1016/j.bbalip.2016.02.020

Cited by 18 publications

(14 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miRNAs regulate all phases of lipoprotein metabolism (Elmen et al, 2008;Esau et al, 2006;Marquart et al, 2010;Rayner et al, 2010). miRNAs repress the expression of genes involved in lipoprotein packaging (ApoB) and secretion (MTP), uptake (LDLR and SR-B1), and cholesterol efflux (ABCA1), and can influence hyperlipidemia and the development of atherosclerosis, as reviewed in (Aryal et al, 2017;Feinberg and Moore, 2016;Zhou et al, 2016). miRNAs also influence lipid metabolism in Alzheimer's disease, as reviewed in (Goedeke et al, 2014;Yoon et al, 2016).…”

Section: Overview Of Mirnas In Lipid Metabolismmentioning

confidence: 99%

The impact of lipids, lipid oxidation, and inflammation on AMD, and the potential role of miRNAs on lipid metabolism in the RPE

Jun

Datta

Wang

et al. 2019

Experimental Eye Research

View full text Add to dashboard Cite

The accumulation of lipids within drusen, the epidemiologic link of a high fat diet, and the identification of polymorphisms in genes involved in lipid metabolism that are associated with disease risk, have prompted interest in the role of lipid abnormalities in AMD. Despite intensive investigation, our understanding of how lipid abnormalities contribute to AMD development remains unclear. Lipid metabolism is tightly regulated, and its dysregulation can trigger excess lipid accumulation within the RPE and Bruch's membrane. The high oxidative stress environment of the macula can promote lipid oxidation, impairing their original function as well as producing oxidation-specific epitopes (OSE), which unless neutralized, can induce unwanted inflammation that additionally contributes to AMD progression. Considering the multiple layers of lipid metabolism and inflammation, and the ability to simultaneously target multiple pathways, microRNA (miRNAs) have emerged as important regulators of many age-related diseases including atherosclerosis and Alzheimer's disease. These diseases have similar etiologic characteristics such as lipid-rich deposits, oxidative stress, and inflammation with AMD, which suggests that miRNAs might influence lipid metabolism in AMD. In this review, we discuss the contribution of lipids to AMD pathobiology and introduce how miRNAs might affect lipid metabolism during lesion development. Establishing how miRNAs contribute to lipid accumulation in AMD will help to define the role of lipids in AMD, and open new treatment avenues for this enigmatic disease.

show abstract

Section: Overview Of Mirnas In Lipid Metabolismmentioning

confidence: 99%

The impact of lipids, lipid oxidation, and inflammation on AMD, and the potential role of miRNAs on lipid metabolism in the RPE

Jun

Datta

Wang

et al. 2019

Experimental Eye Research

View full text Add to dashboard Cite

show abstract

“… 77 ApoB containing low density lipoproteins, whose dysregulation contributes to atherosclerosis, are produced in the liver and their synthesis/assembly is known to be regulated by miR-122, miR-34a and miR-30c. 78 Also, liver production of HDL is inhibited by miR-33, which blocks cholesterol efflux to apolipoprotein A1 by interfering with the expression of the adenosine triphosphate binding cassette (ABC) transporter. 79 Conditions such as hyperlipidaemia stimulate the arterial endothelial cells to express different adhesion molecules (eg, vascular adhesion molecule-1, intracellular adhesion molecule-1 and E-selectin), which participate in capturing leukocytes on their surfaces, and this process along with the formation of macrophage foam cells are involved in the formation of atherosclerotic plaques.…”

Section: Functions Of Circrnas and Mirnas In The Heartmentioning

confidence: 99%

Significance of non-coding circular RNAs and micro RNAs in the pathogenesis of cardiovascular diseases

Zhao

2018

J Med Genet

View full text Add to dashboard Cite

Heart failure, coronary artery disease and myocardial infarction are the most prominent cardiovascular diseases contributing significantly to death worldwide. In the majority of situations, except for surgical interventions and transplantation, there are no reliable therapeutic approaches available to address these health problem. Despite several advances that led to the development of biomarkers and therapies based on the renin–angiotensin system, adrenergic pathways, etc, more definitive and consistent biomarkers and specific target based molecular therapies are still being sought. Recent advances in the field of genomic research has helped in identifying non-coding RNAs, including circular RNAs, piRNAs, micro RNAs, and long non-coding RNAs, that play a significant role in the regulation of gene expression and function and have direct impact on pathophysiological mechanisms. This new knowledge is currently being explored with much hope for the development of novel treatments and biomarkers. Circular RNAs and micro RNAs have been described in myocardium and aortic valves and were shown to be involved in the regulation of pathophysiological processes that potentially contribute to cardiovascular diseases. Approximately 32 000 human exonic circular RNAs have been catalogued and their functions are still being ascertained. In the heart, circular RNAs were shown to bind micro RNAs in a specific manner and regulate the expression of transcription factors and stress response genes, and expression of these non-coding RNAs were found to change in conditions such as cardiac hypertrophy, heart failure and cardiac remodelling, reflecting their significance as diagnostic and prognostic biomarkers. In this review, we address the present state of understanding on the biogenesis, regulation and pathophysiological roles of micro and circular RNAs in cardiovascular diseases, and on the potential future perspectives on their use as biomarkers and therapeutic agents.

show abstract

“…miR-30c inhibits MTP expression via binding to the 3′ UTR of MTP mRNA and induces post-transcriptional degradation leading to reduced assembly of apoB-containing lipoproteins [ 68 , 69 ]. In the case of miR-122, it decreases MTP expression by yet an unknown mechanism [ 106 ].…”

Section: Mirs As Therapeutic Target and Tool For Fh Therapymentioning

confidence: 99%

MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?

Momtazi

Banach

Pirro

et al. 2017

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Familial hypercholesterolemia (FH) is the most common inherited form of dyslipidemia and a major cause of premature cardiovascular disease. Management of FH mainly relies on the efficiency of treatments that reduce plasma low-density lipoprotein (LDL) cholesterol (LDL-C) concentrations. MicroRNAs (miRs) have been suggested as emerging regulators of plasma LDL-C concentrations. Notably, there is evidence showing that miRs can regulate the post-transcriptional expression of genes involved in the pathogenesis of FH, including LDLR, APOB, PCSK9, and LDLRAP1. In addition, many miRs are located in genomic loci associated with abnormal levels of circulating lipids and lipoproteins in human plasma. The strong regulatory effects of miRs on the expression of FH-associated genes support of the notion that manipulation of miRs might serve as a potential novel therapeutic approach. The present review describes miRs-targeting FH-associated genes that could be used as potential therapeutic targets in patients with FH or other severe dyslipidemias.

show abstract

MicroRNAs regulating apolipoprotein B-containing lipoprotein production

Cited by 18 publications

References 84 publications

The impact of lipids, lipid oxidation, and inflammation on AMD, and the potential role of miRNAs on lipid metabolism in the RPE

The impact of lipids, lipid oxidation, and inflammation on AMD, and the potential role of miRNAs on lipid metabolism in the RPE

Significance of non-coding circular RNAs and micro RNAs in the pathogenesis of cardiovascular diseases

MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?

Contact Info

Product

Resources

About